Altaris Appoints Tim Callahan, Shawn Cavanagh and Rafael Torres as Operating Partners
Mr. Callahan has over 25 years of board and operational leadership experience in the biopharmaceutical industry, most recently serving as SVP, Commercial Operations for Actavis Plc (subsequently sold to AbbVie). Mr. Callahan has served on the boards of public, private, and non-profit healthcare organizations, he served as a Senior Advisor to McKinsey & Company, and he holds a Bachelor of Science degree in Applied Economics and Business Management from Cornell University. Mr. Callahan currently serves on the Board of Directors of CMP Pharma and will be joining the board of Padagis upon the completion of the carveout from Perrigo, which is expected to close in the third quarter of 2021.
Mr. Cavanagh has over thirty years of experience in the pharmaceutical services industry, predominantly with contract development and manufacturing organizations. Previously, Mr. Cavanagh was President, Chief Operating Officer, and member of the Board of Directors at Cambrex Corporation. Mr. Cavanagh has also held leadership roles at Lonza, where he served as President of Lonza Bioscience. He holds a degree in Chemical Engineering from the University of New Hampshire. Mr. Cavanagh serves as the Executive Chairman of Kindeva.
Mr. Torres was previously the head of Corporate Development & Strategy at Varian Medical Systems (NYSE:VAR), which was recently sold to Siemens Healthineers for $16.4 billion. Prior to Varian, Mr. Torres spent 14 years at GE, where he led the healthcare investing teams at GE Equity and GE Ventures. Mr. Torres received a BA in Economics from Universidad del Pacifico in Lima, Peru, and an MBA from Harvard Business School. Mr. Torres serves on the Board of Directors of Analogic and HealthTronics.
Altaris is an investment firm focused exclusively on the healthcare industry. Altaris seeks to invest in companies that deliver value to the healthcare system and improve patient outcomes by providing innovative products and services. Since inception in 2003, Altaris has invested in more than 40 companies across its five main investment funds. Altaris has $5.6 billion of equity capital under active management and is headquartered in New York, NY. For more information, visit www.altariscap.com.